{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "currency": "USD", "regularMarketChangePercent": 3.078558, "regularMarketPrice": 48.55, "marketState": "REGULAR", "regularMarketChange": 1.4500008, "regularMarketTime": 1684172111, "regularMarketDayHigh": 48.715, "regularMarketDayRange": "46.93 - 48.715", "regularMarketDayLow": 46.93, "regularMarketVolume": 264044, "regularMarketPreviousClose": 47.1, "bid": 48.4, "ask": 48.44, "bidSize": 11, "askSize": 8, "fullExchangeName": "NasdaqGS", "financialCurrency": "USD", "regularMarketOpen": 47.0, "averageDailyVolume3Month": 619140, "averageDailyVolume10Day": 716200, "fiftyTwoWeekLowChange": 15.189999, "fiftyTwoWeekLowChangePercent": 0.45533568, "fiftyTwoWeekRange": "33.36 - 68.68", "fiftyTwoWeekHighChange": -20.130001, "fiftyTwoWeekHighChangePercent": -0.29309845, "fiftyTwoWeekLow": 33.36, "fiftyTwoWeekHigh": 68.68, "earningsTimestamp": 1683234000, "earningsTimestampStart": 1690369140, "earningsTimestampEnd": 1690804800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -9.95, "epsForward": -6.25, "exchange": "NMS", "shortName": "Ultragenyx Pharmaceutical Inc.", "longName": "Ultragenyx Pharmaceutical Inc.", "messageBoardId": "finmb_117471985", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "firstTradeDateMilliseconds": 1391178600000, "priceHint": 2, "epsCurrentYear": -7.99, "priceEpsCurrentYear": -6.0763454, "sharesOutstanding": 70814496, "bookValue": 3.121, "fiftyDayAverage": 41.3324, "fiftyDayAverageChange": 7.217598, "fiftyDayAverageChangePercent": 0.17462324, "twoHundredDayAverage": 42.9213, "twoHundredDayAverageChange": 5.6287003, "twoHundredDayAverageChangePercent": 0.13114002, "marketCap": 3546072576, "forwardPE": -7.7679996, "priceToBook": 15.555911, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Ultragenyx Pharmaceutical", "symbol": "RARE"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "60 Leveroni Court", "city": "Novato", "state": "CA", "zip": "94949", "country": "United States", "phone": "415 483 8800", "website": "https://www.ultragenyx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.", "fullTimeEmployees": 1311, "companyOfficers": [{"maxAge": 1, "name": "Dr. Emil D. Kakkis M.D., Ph.D.", "age": 62, "title": "Founder, Pres, CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": {"raw": 1366354, "fmt": "1.37M", "longFmt": "1,366,354"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1888758, "fmt": "1.89M", "longFmt": "1,888,758"}}, {"maxAge": 1, "name": "Mr. John Richard Pinion II", "age": 56, "title": "Chief Quality Operations Officer & Exec. VP of Translational Sciences", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 806193, "fmt": "806.19k", "longFmt": "806,193"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Erik  Harris", "age": 51, "title": "Exec. VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 848237, "fmt": "848.24k", "longFmt": "848,237"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Theodore A. Huizenga", "age": 51, "title": "Sr. VP, Corp. Controller & Principal Accounting Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Dennis Karl Huang", "age": 57, "title": "Chief Technical Operations Officer & Gene Therapy Operations and Exec. VP", "yearBorn": 1965, "fiscalYear": 2015, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Danielle  Keatley", "title": "Sr. Director of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Karah Herdman Parschauer J.D.", "age": 44, "title": "Chief Legal Officer & Exec. VP", "yearBorn": 1978, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ernie W. Meyer", "age": 58, "title": "Chief HR Officer & Exec. VP", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Thomas R. Kassberg", "age": 62, "title": "Chief Bus. Officer & Exec. VP", "yearBorn": 1960, "fiscalYear": 2019, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cordelia  Leonard", "age": 62, "title": "Sr. VP of Regulatory Affairs", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 1, "compensationRisk": 4, "shareHolderRightsRisk": 7, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}